The FDA on April 29, 2024, granted traditional approval to TIVDAK® for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy. Tisotumab vedotin-tftv previously received accelerated approval for this indication. TIVDAK® is a product of Seagen Inc., now a part of Pfizer Inc.
Bottom Ad
Advertisement
Subscribe
